29/08/2014 20:26:22 Free Membership Login

Cubist News (NASDAQ:CBST)

DateTimeSource
Headline
08/26/20148:30AMBWCubist to Present New Data from Antibiotics Portfolio at 54th Interscience Conference on Antimicrobial Agents & Chemotherapy ...
Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today announced that it will present new data at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), September 5-9 in Washington, D.C. Data highlighted will offer insights into Cubist’s commitment to identifying treatments for drug-resistant Gram-positive... More...>>
08/25/20149:00AMBWCubist to Present at Morgan Stanley Global Healthcare Conference
Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today announced that Mike Bonney, Cubist’s CEO, will present at the Morgan Stanley Global Healthcare Conference on Monday, September 8, to discuss the company’s business activities, financial outlook, and current news. The presentation will be held at the Grand Hyatt New... More...>>
08/22/20147:30AMBWCubist Announces EMA Acceptance of Ceftolozane/Tazobactam Marketing Authorization Application for Review
Cubist Pharmaceuticals, Inc. (NASDAQ:CBST) today announced that the European Medicines Agency (EMA) has accepted for review the Company’s Marketing Authorization Application (MAA) for its investigational antibiotic ceftolozane/tazobactam. Cubist is seeking approval of ceftolozane/tazobactam for the treatment of complicated... More...>>
08/22/20147:30AMBWCubist annonce l’acceptation par l’EMA du dossier de demande d’autorisation de mise sur le marché du ceftolozane/tazob...
Cubist Pharmaceuticals, Inc. (NASDAQ : CBST) a annoncé aujourd’hui que l’Agence européenne des médicaments (EMA) a accepté d’étudier la demande d’autorisation de mise sur le marché (MAA) de la société pour son candidat antibiotique ceftolozane/tazobactam. Cubist recherche l’approbation du ceftolozane/tazobactam... More...>>
08/22/20147:30AMBWCubist meldet Annahme des Marktzulassungsantrags für Ceftolozan/Tazobactam bei der EMA
Cubist Pharmaceuticals, Inc. (NASDAQ:CBST) gab heute bekannt, dass die Europäische Arzneimittelagentur (EMA) den Antrag des Unternehmens auf das Inverkehrbringen (MAA) seines Prüfantibiotikums Ceftolozan/Tazobactam zur Prüfung angenommen hat. Cubist beantragt damit die Zulassung von Ceftolozan/Tazobactam für die Behandlung... More...>>
08/08/20145:47PMBWCubist Pharmaceuticals Issues Voluntary Nationwide Recall of Nine Lots of CUBICIN (daptomycin for injection) 500 mg in 10 mL ...
Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today announced it is voluntarily recalling nine lots of CUBICIN® (daptomycin for injection) to the user level following complaints of foreign particulate matter in reconstituted vials. The administration of particulate matter, if present in an intravenous drug, poses a potential... More...>>
08/06/20148:42AMBWCubist Pharmaceuticals Issues Voluntary U.S. Recall of Certain Lots of CUBICIN (daptomycin for injection) 500 mg in 10 mL sin...
Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today announced it is voluntarily recalling certain lots of CUBICIN® (daptomycin for injection) to the user level due to the potential presence of glass particulate matter in vials produced by a contract manufacturer. Please click here for the list of affected CUBICIN lot information... More...>>
08/06/20148:00AMBWCubist Pharmaceuticals Issues Voluntary U.S. Recall of Certain Lots of CUBICIN (daptomycin for injection) 500 mg in 10 mL sin...
Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today announced it is voluntarily recalling certain lots of CUBICIN® (daptomycin for injection) to the user level due to the potential presence of glass particulate matter in vials produced by a contract manufacturer. Please click here for the list of affected CUBICIN lot information... More...>>
08/05/20148:30AMBWCubist’s Once-daily SIVEXTRO™ (tedizolid phosphate) Available for Physician and Hospital Order in I.V. and Oral Formulati...
SIVEXTRO is a short, six-day course of therapy to treat serious skin infections, including those caused by MRSA Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) announces SIVEXTRO™ (tedizolid phosphate) indicated for the treatment of adult acute bacterial skin and skin structure infections (ABSSSI) is now available in the... More...>>
07/28/20149:00AMBWCubist to Present at August Investor Conference
Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today announced that company management will discuss Cubist’s business activities and financial outlook at investor conferences during August 2013. On Wednesday, August 6, Robert Perez, Cubist President and COO, and Michael Tomsicek, Cubist SVP and Chief Financial Officer... More...>>
07/22/20144:00PMBWCubist Reports Second Quarter 2014 Financial Results
Total Net Revenues of $294.4 Million, Up 14% Over Q2 2013 Non-GAAP Adjusted Operating Income of $41.4 Million; GAAP Operating Income of $42.2 Million Non-GAAP Diluted EPS of $0.23; GAAP Diluted EPS of $0.30 Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today announced results for the second quarter ended June 30, 2014. The... More...>>
07/15/20149:00AMBWCubist to Announce Second Quarter 2014 Financial Results on Tuesday, July 22, 2014
Earnings Conference Call & Webcast at 5:00 pm ET Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) will issue its second quarter 2014 financial results at 4:00 p.m. ET on Tuesday, July 22, 2014. In connection with this announcement, Cubist will host a conference call and live audio webcast presentation at 5:00 p.m. ET that... More...>>
06/23/201410:25AMBWLe médicament SIVEXTROMC (phosphate de tedizolid), de Cubist, est approuvé aux États-Unis pour le traitement des infection...
SIVEXTRO offre aux médecins une nouvelle option : une brève série de traitements administrés par voie intraveineuse ou orale une fois par jour pendant six jours Cubist Pharmaceuticals, Inc. (NASDAQ : CBST) a annoncé aujourd'hui que la Food and Drug Administration (FDA) des États-Unis a approuvé SIVEXTROMC (phosphate... More...>>
06/22/20141:58AMBWSIVEXTRO™ (Tedizolid Phosphat) von Cubist zur Behandlung schwerer Hautinfektionen, auch durch MRSA, in den USA zugelassen
SIVEXTRO bietet Ärzten kurze, sechstätige Behandlung mit Wahlmöglichkeit zwischen einmal täglicher intravenöser oder oraler Verabreichung Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) gab heute bekannt, dass die US-Gesundheitsbehörde FDA SIVEXTRO™ (Tedizolid Phosphat) zur Behandlung erwachsener Patienten mit akuten... More...>>
06/20/20146:00PMBWCubist’s SIVEXTRO™ (tedizolid phosphate) Approved in U.S. to Treat Serious Skin Infections—Including Those Caused by MRSA
SIVEXTRO offers a short six-day course of therapy to physicians in once daily I.V. and oral treatment options Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) announced today the U.S. Food and Drug Administration (FDA) approved SIVEXTRO™ (tedizolid phosphate) for the treatment of adult acute bacterial skin and skin structure... More...>>
06/20/20149:20AMDJNU.S. Hot Stocks: Hot Stocks to Watch
Among the companies with shares expected to actively trade in Friday's session are CarMax Inc. (KMX), Darden Restaurants Inc. (DRI) and Oracle Corp. (ORCL). AK Steel Holding Corp. (AKS) said second-quarter results will be hurt by lower production at blast furnaces, a move the company said was necessary because ice coverage... More...>>
06/19/20144:30PMBWCubist Announces Acceptance of Ceftolozane/Tazobactam New Drug Application with Priority Review
Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today announced that the U.S. Food and Drug Administration (FDA) has accepted the Company’s New Drug Application (NDA) for its investigational antibiotic ceftolozane/tazobactam with Priority Review. The FDA has assigned a Prescription Drug User Fee Act (PDUFA) action date of... More...>>
06/06/20149:00AMBWCubist Announces Publication of Pivotal Data from SIVEXTRO™ (tedizolid phosphate) ESTABLISH-2 Clinical Trial in The Lancet ...
Results from first prospectively designed Phase 3 clinical trial consistent with final FDA guidance for acute bacterial skin and skin structure infections (ABSSSI) Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today announced that The Lancet Infectious Diseases published online the positive results from ESTABLISH-2, a pivotal... More...>>
06/06/20149:00AMBWCubist veröffentlicht zulassungsrelevante Daten der klinischen Studie ESTABLISH-2 zu SIVEXTRO™ (Tedizolid-Phosphat) im Jou...
Ergebnisse der ersten prospektiv konzipierten klinischen Phase-3-Studie entsprechen endgültiger FDA-Leitlinie für akute bakterielle Infektionen der Haut und Hautstrukturen Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) gab heute bekannt, dass das Journal Lancet Infectious Diseases die positiven Ergebnisse der zulassungsrelevanten... More...>>
06/06/20149:00AMBWCubist annonce la publication de résultats importants de l'essai clinique ESTABLISH-2 sur SIVEXTRO™ (phosphate de tedizoli...
Résultats du premier essai clinique prospectif de phase III conforme à la ligne directrice finale de la FDA sur les infections bactériennes aiguës de la peau et des structures cutanées (ABSSSI) Cubist Pharmaceuticals, Inc. (NASDAQ : CBST) a annoncé aujourd'hui que The Lancet Infectious Diseases a mis en ligne les... More...>>


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE and AMEX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

1 site:2 us nasdaq cbst140829 20:26